A carregar...
Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
Carfilzomib (Cfz) has been associated with an ~5% incidence of unexplained and unpredictable cardiovascular toxicity in clinical trials. We therefore implemented a detailed, prospective, clinical cardiac and renal evaluation of 62 Cfz-treated myeloma patients, including serial blood pressure (BP), c...
Na minha lista:
| Publicado no: | Blood Cancer J |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4742629/ https://ncbi.nlm.nih.gov/pubmed/26771810 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2015.112 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|